Testing targeted imaging and therapy for advanced solid tumors
Part of Cancer, Digestive system, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer that cannot be removed with surgery, and it must be one of the listed cancer types (or another cancer with confirmed CA IX).
- You must have had enough prior cancer treatment for your specific cancer type (different rules by kidney, pancreas, colon, bladder, and head/neck groups).
- A recent scan (CT or MRI) within 4 weeks must show at least one measurable, non-irradiated tumor spot that is not already treated with radiation.
- You must be able to provide tumor tissue from a recent fresh biopsy or an older archival sample (for some groups, preferably taken after your last treatment).
- No major surgery in the last 12 weeks, and you must be able to lie still in the scanner during the imaging/scan time.
- You cannot have had prior CA IX (carbonic anhydrase IX) targeted treatment recently, and there are time-window limits on prior radiation and other radioactive medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This trial tests a special radioactive medicine (177Lu-CTR-FAPI) for people with advanced digestive cancers that have high FAP expression. The medicine targets a protein on cancer cells to deliver radiation directly to tumors, potentially slowing their growth.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
Hear when a new Clear Cell Renal Cell Cancer (ccRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.